Thanks Mason, I have to admit I read Allogene and thought Arovella. I've asked for my comment to be removed.
I have no idea how you can possibly state Genocury has revolutionised CAR T treatment off of a N=1 press release from an effectively unknown company with next to no transparency. FDA stating it's a safety concern has nothing to do with Genocury's claims.
IMU Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)